1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Mediastinal Large B-cell Lymphoma: new trials by email Literature Review of Mediastinal Large B-cell Lymphoma trials Research Report on Mediastinal Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 | |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Pembrolizumab - Mediastinal Large B-cell Lymphoma, Richter Syndrome | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2015-12-02 | 2023-07-27 |
Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1)
Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · Rituximab (1) · pembrolizumab (1)
Merck Sharp & Dohme LLC (1) · University of Arizona (1)
United States (1)
PMID 31609651, PMID 32544980, PMID 37130017
2015 (1)